The role of indacaterol for chronic obstructive pulmonary disease (COPD).

about

COPD: the patient perspective Olodaterol attenuates citric acid-induced cough in naïve and ovalbumin-sensitized and challenged guinea pigs

P2860

Q26764894-EACA0771-2B6E-4056-B610-FD6DB1CF1060 Q35190258-063BC969-9D09-4D2E-8866-7B3E2381874A

P2860

The role of indacaterol for chronic obstructive pulmonary disease (COPD).

Item

http://www.wikidata.org/entity/Q41853545

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

The role of indacaterol for chronic obstructive pulmonary disease (COPD).

@en

type

Item

label

The role of indacaterol for chronic obstructive pulmonary disease (COPD).

@en

prefLabel

The role of indacaterol for chronic obstructive pulmonary disease (COPD).

@en

P1476

The role of indacaterol for chronic obstructive pulmonary disease (COPD).

@en

P2093

Emanuele Stirpe

http://www.w3.org/2001/XMLSchema#string

Floriana Bardaro

http://www.w3.org/2001/XMLSchema#string

Mario Cazzola

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study

Indacaterol therapy in patients with COPD not receiving other maintenance treatment

Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.

Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.

Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials.

Safety of indacaterol in the treatment of patients with COPD.

Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease.

A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use.

P304

559-566

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3978/J.ISSN.2072-1439.2013.07.35

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23991316

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease

P932

3755680

http://www.w3.org/2001/XMLSchema#string

The role of indacaterol for chronic obstructive pulmonary disease (COPD).

about

P2860

P2860

The role of indacaterol for chronic obstructive pulmonary disease (COPD).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932